SummaryBiotin, also known as vitamin B7 or vitamin H, is one of the B vitamins. It is essential for the metabolism of carbohydrates, fats, and proteins. Biotin is naturally present in a variety of foods, including egg yolks, liver, nuts, seeds, and certain vegetables such as sweet potatoes and spinach. The discoverer of biotin is considered to be Hungarian-American biochemist Paul Gyorgy, who first isolated biotin from egg yolks in 1936. Today, biotin is used for a variety of indications, both as a dietary supplement and as a treatment for certain medical conditions such as diabetes, eczema, muscular dystrophy, and adrenoleukodystrophy. |
Drug Type Small molecule drug |
Synonyms (+)-cis-Hexahydro-2-oxo-1H-thieno[3,4]imidazole-4-valeric acid, (3aS,4S,6aR)-Hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-valeric acid, 5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoic acid + [16] |
Target |
Action inhibitors |
Mechanism ABCD1 inhibitors(ATP Binding Cassette Subfamily D Member 1 inhibitors) |
Active Indication |
Originator Organization- |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC10H16N2O3S |
InChIKeyYBJHBAHKTGYVGT-ZKWXMUAHSA-N |
CAS Registry58-85-5 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus | - | - | - |
Eczema | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Sclerosis | NDA/BLA | European Union | - | |
Adrenoleukodystrophy | Phase 3 | France | 01 Oct 2014 | |
Adrenoleukodystrophy | Phase 3 | Germany | 01 Oct 2014 | |
Adrenoleukodystrophy | Phase 3 | Spain | 01 Oct 2014 | |
Multiple Sclerosis, Chronic Progressive | Phase 3 | France | 01 Oct 2013 | |
Optic Neuritis | Phase 3 | France | 01 Oct 2013 | |
Optic Neuritis | Phase 3 | United Kingdom | 01 Oct 2013 | |
Vision, Low | Phase 3 | France | 01 Oct 2013 | |
Vision, Low | Phase 3 | United Kingdom | 01 Oct 2013 | |
Charcot-Marie-Tooth Disease, Type Ia | Phase 2 | France | 05 Dec 2016 |
Not Applicable | - | nxqazovnoy(kdbgevlcyu) = sxuhuasyvt axnqsrvqno (gmnfrzfejq ) View more | - | 01 Jun 2024 | |||
Not Applicable | - | 61 | wpctiskwkn(kbroieczej) = ecpnuydiwg rmlnlylvlr (qzsxwfredg ) View more | Positive | 11 Oct 2023 | ||
wpctiskwkn(kbroieczej) = yihcljqawh rmlnlylvlr (qzsxwfredg ) View more | |||||||
Not Applicable | Congenital Disorders of Glycosylation biotinidase activity | 29 | zzacbnktbf(jccczpnzpr) = bkbtnkfias nyhhqhvbay (gjpshaszym ) | - | 30 Aug 2023 | ||
Not Applicable | - | - | aqwetxbxsz(jzgaxwwjov) = mkalzeqorn pnmlvyyaoe (ckshpldiwz ) | - | 01 Nov 2022 | ||
Not Applicable | 889 | qfbyjiurwi(dcgolxwoyo) = Thirty-one patients (4.7%) in the HDB group were found to have laboratory test interference buzjaakdrv (spaxyltvop ) | - | 03 May 2022 | |||
Not Applicable | Adrenal Insufficiency ACTH | morning cortisol | DHEA-S | - | Hydrocortisone therapy | cryhlaxlig(wmnxvrhsqi) = nckubwssmc bgeiorffhh (lulypihrkk, 7.2–63.3) | - | 03 May 2021 | |
Phase 3 | 642 | maaufpjqmh(jsbtxwinkj) = mjmtjkfpod pofosxtoqm (yxwfvshybk ) View more | Negative | 01 Dec 2020 | |||
Placebo | maaufpjqmh(jsbtxwinkj) = hkkzacclmk pofosxtoqm (yxwfvshybk ) View more | ||||||
Phase 3 | 642 | PLACEBO (GROUP 1) | vtjesykuya(oeubbcoxum) = iophfwqlab ngxwxetxot (sdddrjwvku, mfbkrefpjj - sdznjbuxug) View more | - | 23 Nov 2020 | ||
(GROUP 2) | vtjesykuya(oeubbcoxum) = nvfuhuqxzx ngxwxetxot (sdddrjwvku, gnrakfdlsv - ksqofsnnuf) View more | ||||||
Phase 1 | - | 6 | boiubjnabp(jyitgrfcjj) = mdwlflwfeo ocgbwjwipy (pafzwbbsdp, 16.9) View more | - | 02 Nov 2020 | ||
Phase 2 | 15 | fwsumkfwic(hgarjlxqct) = hmufdnowgx ehgoboxmem (zxuobjopjn, 11.45) View more | - | 02 Nov 2020 |